Erectile Dysfunction Drugs Market
The MRFR reports suggest that the global erectile dysfunction drugs market is projected to acquire a size of over USD 2930 million at a CAGR of 3.5% during the assessment timeframe.
Erectile Dysfunction (E.D.) refers primarily to the consistent trouble achieving and maintaining an erection adequate to have intercourse. It is generally caused by stress and emotional wellness concerns. The global erectile dysfunction drugs market has witnessed massive growth in recent years. The market’s growth is attributed to the rising appropriation of a stationary way of life, expanding makes of nonexclusive medications, patent expiry of several blockbuster drugs, rising geriatric populace, and growing number of men suffering from this issue. On the other hand, the growth of the erectile dysfunction drugs market is anticipated to be restricted by the growth in accessibility of fake erectile dysfunction drugs, lack of awareness, and high costs associated with these drugs.
Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/1313
Erectile Dysfunction Drugs Market Segment Analysis
The global erectile dysfunction drugs market has been divided into several segments based on drug type, end-user, and region.
Based on drug type, the erectile dysfunction drugs market is split into vitaros (alprostadil cream), Cialis (tadalafil), Viagra (sildenafil citrate), stendra/spedra (avanafil), zydena (udenafil), staxyn/Levitra (vardenafil), and others.
By end-user, the erectile dysfunction drugs market is divided into the online drug store, medical clinic drug stores, and retail drug stores.
Erectile Dysfunction Drugs Market Regional Analysis
The erectile dysfunction drugs market is studied across five major regions, including the Middle East & Africa, Europe, the Americas, and the Asia-Pacific.
The Americas region has been further divided into Latin America and North America. The regional market for erectile dysfunction drugs will likely record the maximum revenue over the forecasted era. The regional market’s growth is being driven by the high medical services consumption, all-around created innovation, and the presence of the patient populace.
The European regional erectile dysfunction drugs market will record significant growth over the review timeframe. The regional market’s growth is being propelled by the assessment activities by regulatory authorities for erectile dysfunction treatments.
Erectile Dysfunction Drugs Market Competitive Analysis
The global erectile dysfunction drugs market has an intensely competitive landscape. The players in the global market are adopting several new strategies such as partnerships, acquisitions, mergers, and product development to strengthen their global market position. The list of leading players in the global erectile dysfunction drugs market includes Meda Pharmaceuticals, Inc., Apricus Biosciences Inc. (U.S), S.K. Chemicals Co. Ltd. (South Korea), Bayer AG (Germany), Pfizer Inc. (U.S), Teva Pharmaceutical Industries Ltd., S.K. Chemicals Co. Ltd., Eli Lily & Co. (U.S), Apricus Biosciences Inc. (U.S)., Vivus Inc., Cristalia Produtos Quimicos Farmaceuticos Ltd., and Dong-A Pharmaceutical Co. Ltd. (South Korea), among several others.
Recent Developments
A prominent supplier of therapeutics for men’s health, Petros Pharmaceuticals, Inc. disclosed positive results for over-the-counter (OTC) draft label comprehension study for STENDRA®, its erectile dysfunction (E.D.) Drug. This Crucial Label Comprehension Study was intended to evaluate the comprehension of a draft STENDRA® Drug Facts Label meant for OTC use. The research is a vital component in the firm’s plans to join in discussions with the FDA to grow the product’s access all through application for a possible OTC pathway.
Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/erectile-dysfunction-drugs-market-1313
Oncotelic Therapeutics, Inc. has signed an exclusive licensing agreement with Autotelic Inc. for approving intranasal apomorphine (“AL-101”). The company aims to build AL-101 via the fast-to-market 505(b)2 regulatory pathway to treat Erectile Dysfunction (“E.D.”) and Parkinson Disease (“P.D.”), particularly phosphodiesterase 5 (“PDE5”) non-responders. Additionally, it also aims to produce AL-101 as the latest class of drug against Female Sexual Dysfunction (“FSD”), including Hypoactive Sexual Desire Disorder (“HSDD”). The drug has exhibited a satisfactory efficacy and safety profile and is phase 3 ready with six clinical trials are done, and approximately 200 patients (2,200 doses) treated.
Browse Related Reports at
Human Immunodeficiency Virus Drugs Market Research Report – Global Forecast till 2027
Anxiety Disorder Treatment Market Research Report – Global Forecast till 2027
Bronchodilators Market Research Report – Global Forecast till 2027
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: sales@marketresearchfuture.com